Treatment of Mantle-Cell Lymphoma
- PMID: 36130009
- DOI: 10.1056/NEJMc2209904
Treatment of Mantle-Cell Lymphoma
Comment in
-
Treatment of Mantle-Cell Lymphoma. Reply.N Engl J Med. 2022 Sep 22;387(12):1148. doi: 10.1056/NEJMc2209904. N Engl J Med. 2022. PMID: 36130010 No abstract available.
Comment on
-
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
Similar articles
-
Treatment of Mantle-Cell Lymphoma.N Engl J Med. 2022 Sep 22;387(12):1147. doi: 10.1056/NEJMc2209904. N Engl J Med. 2022. PMID: 36130008 No abstract available.
-
Treatment of Mantle-Cell Lymphoma.N Engl J Med. 2022 Sep 22;387(12):1146-1147. doi: 10.1056/NEJMc2209904. N Engl J Med. 2022. PMID: 36130007 No abstract available.
-
Treatment of Mantle-Cell Lymphoma. Reply.N Engl J Med. 2022 Sep 22;387(12):1148. doi: 10.1056/NEJMc2209904. N Engl J Med. 2022. PMID: 36130010 No abstract available.
-
Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.Drugs. 2010 Sep 10;70(13):1703-18. doi: 10.2165/11205860-000000000-00000. Drugs. 2010. PMID: 20731477 Review.
-
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.Oncologist. 2013;18(8):954-64. doi: 10.1634/theoncologist.2013-0079. Epub 2013 Jul 30. Oncologist. 2013. PMID: 23900001 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources